Use of Extracorporeal Photopheresis in Kidney Transplantation: Effects on Antibody-Mediated Rejection

Centre Hospitalier Universitaire de Besancon31 enrolled

Overview

This study aims to describe, over a one-year period, the clinical, biological, and histological evolution of a cohort of kidney transplant recipients who developed antibody-mediated rejection and were treated with extracorporeal photopheresis.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Antibody-mediated Rejection in Kidney Transplant

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Kidney transplant recipients followed at the University Hospitals of Besançon and Lille between September 1, 2016, and August 31, 2023 * Patients with antibody-mediated rejection (as confirmed by histological analysis of the renal biopsy) * Rejection treated with extracorporeal photopheresis * Subjects who do not object to the use of their personal data and/or biological samples * Subjects affiliated with, or beneficiaries of, the French social security system Exclusion Criteria: * Patients with acute rejection * Pregnant women, women in labor, or breastfeeding mothers * Individuals deprived of liberty by judicial or administrative decision; individuals receiving compulsory psychiatric care; or individuals admitted to a healthcare or social institution for reasons other than research participation * Minors * Adults under legal protection or unable to provide informed consent * Subjects without health insurance coverage * Subjects currently within an exclusion period from another study, or as listed in the "national volunteer registry"

Locations (1)

Centre Hospitalier Universitaire de Besançon

Besançon, France

RECRUITING

Outcomes

Primary Outcomes

Number of participants with response to extracorporeal photopheresis (ECP) at 1 year

Response is defined as either: * stable serum creatinine at 1 year after initiation of ECP, corresponding to a variation within ±20% of baseline serum creatinine (responder); or * a reduction in the slope of creatinine clearance decline following initiation of ECP compared with the pre-treatment trajectory (partial responder). Participants meeting either criterion are considered responders for the primary efficacy analysis.

Time frame: One year after initiation of ECP

Central Contacts

Charline Vauchy, PhD.

CONTACT

+33381218875 cvauchy@chu-besancon.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.